Timothy Wollaeger
Managing Director
Sanderling Ventures

Timothy Wollaeger has more than 30 years experience in the medical products and biotechnology fields in both corporate management and venture capital. Wollaeger joined Sanderling Ventures as a managing director in 2002, and opened the firm's San Diego office. Wollaeger serves on the board of directors for several Sanderling portfolio companies, including Asteres, Triage Wireless, CalciMedica and REN. He is chairman of the board of directors for Chimerix and is chairman and chief executive officer of Harkness Pharmaceuticals. Prior to joining Sanderling, Wollaeger founded the venture capital firm Kingsbury Capital Partners in 1994. At Kingsbury, seed and early stage investing was combined with active management and portfolio companies included Aurora Biosciences, Amylin Pharmaceuticals (NASDAQ: AMLN), Senomyx (NASDAQ: SNMX), and Althea Technologies. Wollaeger was named E&Y San Diego’s Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001.

Wollaeger helped found Columbia Hospital Corporation in 1990 and was a senior vice president and member of the board of directors until 1994. In 1986, Wollaeger became a founding general partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found Pyxis, Biosite, Amlin Pharmaceuticals (NASDAQ: AMLN) and Vical (NASDAQ: VICL). In 1983, Wollaeger joined Hybritech, Inc., San Diego's first biotechnology company, as vice president and chief financial officer. He began his life science career at Baxter International where he was manager of operations analysis. His last position was vice president and general manager of the company's operations in Mexico.

Wollaeger earned a Bachelor of Arts degree in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned a Masters of Business Administration from The Stanford Graduate School of Business in 1971.